Results of a prospective study for the treatment of unilateral retinoblastoma

Pediatric Blood and Cancer

Volumn 55, Issue 1, 2010, Pages 60-66

  Chantada, Guillermo L ^a   Fandiño, Adriana C ^a   Guitter, Myriam R ^a   Raslawski, Elsa C ^a   Dominguez, Julieta L ^a   Manzitti, Julio ^a   De Dávila, María T G ^a   Zubizarreta, Pedro ^a   Scopinaro, Marcelo ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Chemotherapy; Retinoblastoma; Risk factors; Unilateral

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IDARUBICIN; THIOTEPA; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER INVASION; CANCER RELAPSE; CANCER RISK; CHILD; CONTROLLED STUDY; DRUG FEVER; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HORMONE DEFICIENCY; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ORAL MUCOSITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINOBLASTOMA; RISK FACTOR; URINARY TRACT INFECTION; VIRAL LOWER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECURRENCE; REPRODUCIBILITY OF RESULTS; RETINAL NEOPLASMS; RETINOBLASTOMA; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 77953280551     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22503     Document Type: Article

References (41)

1. Abramson DH. Retinoblastoma incidence in the United States. Arch Ophthalmol 1990;108:1514.
2. Abramson DH, Schefler AC. Update on retinoblastoma. Retina 2004;24:828-848.
3. Rodriguez-Galindo C, Wilson MW, Chantada G, et al. Retinoblastoma: One world, one vision. Pediatrics 2008;122:e763-e770.
4. Naseripour M, Nazari H, Bakhtiari P, et al. Retinoblastoma in Iran: Outcomes in terms of patients' survival and globe survival. Br J Ophthalmol 2009;93:28-32.
5. Leal-Leal C, Flores-Rojo M, Medina-Sanson A, et al. A multicentre report from the Mexican Retinoblastoma Group. Br J Ophthalmol 2004;88:1074-1077. (Pubitemid 39013153)
6. Chantada G, Fandino A, Davila MT, et al. Results of a prospective study for the treatment of retinoblastoma. Cancer 2004;100:834-842. (Pubitemid 38176864)
7. Chantada GL, Dunkel IJ, de Davila MT, et al. Retinoblastoma patients with high risk ocular pathological features: Who needs adjuvant therapy? Br J Ophthalmol 2004;88:1069-1073.
8. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: A retrospective study of 172 patients treated in a single institution. Cancer 1996;77:1206-1213. (Pubitemid 26080915)
9. Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology 1989;96:217-222.
10. Messmer EP, Heinrich T, Hopping W, et al. Risk factors for metastases in patients with retinoblastoma. Ophthalmology 1991;98:136-141.
11. Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: Metastatic potential and clinical risk factors. Br J Ophthalmol 1993;77:544-548.
12. Schvartzman E, Chantada G, Fandino A, et al. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol 1996;14:1532-1536. (Pubitemid 26134210)
13. Chantada GL, Dunkel IJ, Antoneli CB, et al. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer 2007;49:256-260.
14. Grabowski EF, Abramson DH. Intraocular and extraocular retinoblastoma. Hematol Oncol Clin North Am 1987;1:721-735.
15. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol 1963;67:164-172.
16. Chantada GL, Rossi J, Casco F, et al. An aggressive bone marrow evaluation including immunocytology with GD2 for advanced retinoblastoma. J Pediatr Hematol Oncol 2006;28:369-373. (Pubitemid 43970393)
17. Chantada GL, Casco F, FandinoAC, et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology 2007;114:2083-2089.
18. Chantada GL, Guitter MR, Fandino AC, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer 2009;52:218-222.
19. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer 2000;89:2117-2121.
20. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with highrisk retinoblastoma: A SFOP and SFGM study. Eur J Cancer 1997;33:2368-2375.
21. Ozkan A, Pazarli H, Celkan T, et al. Retinoblastoma in Turkey: Survival and clinical characteristics 1981-2004. Pediatr Int 2006;48:369-373.
22. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002;120:1653-1658.
23. Chantada GL, Fandino AC, Raslawski EC, et al. Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatr Blood Cancer 2005;44:455-460.
24. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: Is chemotherapy a factor? Ophthalmology 2007;114:1378-1383.
25. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115:1398-1404, 1404 e1391.
26. Wilimas JA, Wilson MW, Haik BG, et al. Development of retinoblastoma programs in Central America. Pediatr Blood Cancer 2009;53:42-46.
27. Sitorus RS, Moll AC, Suhardjono S, et al. The effect of therapy refusal against medical advice in retinoblastoma patients in a setting where treatment delays are common. Ophthalmic Genet 2009;30:31-36.
28. Bowman RJ, Mafwiri M, Luthert P, et al. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer 2008;50:160-162.
29. Meadows AC, Dunkel IJ, Friedman D, et al. Children's Oncology Group trials for retinoblastoma. In: Singh A, Damato B, Pe'er J, Murphree AL, Perry JD, editors. Essentials of ophthalmic oncology. Thorofare: SLACK Incorporated; 2009. pp.204-205.
30. Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol 2002;47:1-16.
31. Chantada GL, Doz F, Orjuela M, et al. World disparities in risk definition and management of retinoblastoma: A report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer 2008;50:692-694.
32. Eagle RC, Jr., High-risk features and tumor differentiation in retinoblastoma: A retrospective histopathologic study. Arch Pathol Lab Med 2009;133:1203-1209.
33. Orellana ME, Fernandes BF, Arean C, et al. Clinical pathologic study of a cohort of patients with retinoblastoma from a developing country. J Pediatr Ophthalmol Strabismus 2009;46:294-299.
34. Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001;119:41-48.
35. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002;120:923-931.
36. Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol 2007;29:700-704.
37. Cuenca A, Giron F, Castro D, et al. Microscopic scleral invasion in retinoblastoma: Clinicopathological features and outcome. Arch Ophthalmol 2009;127:1006-1010.
38. Howarth C, Meyer D, Hustu HO, et al. Stage-related combined modality treatment of retinoblastoma. Results of a prospective study. Cancer 1980;45:851-858.
39. Zelter M, Damel A, Gonzalez G, et al. A prospective study on the treatment of retinoblastoma in 72 patients. Cancer 1991;68:1685-1690.
40. Antoneli CB, Steinhorst F, de Cassia Braga Ribeiro K, et al. Extraocular retinoblastoma: A 13-year experience. Cancer 2003;98:1292-1298.
41. Yamane S, Shirai C, Arimoto A, et al. Disseminated retinoblastoma successfully treated with myeloablative chemotherapy-Implication for molecular detection of minimal residual disease. Bone Marrow Transplant 1999;23:971-974.